April 25th 2025
When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
AMCP’s Adam Colborn Discusses Aspects of the IRA and Impact on Patients
October 17th 2024A lot of attention has been on the drug price negotiation aspects of the Inflation Reduction Act (IRA), but the implementation of out-of-pocket smoothing is something to keep an eye on, said Adam Colborn, JD, of AMCP.
Watch
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
October 17th 2024Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Read More
Cost Effectiveness Varies in TAS-102 Plus Bevacizumab Third Line Treatment
October 10th 2024Patients with refractory metastatic colorectal cancer could use trifluridine/tipiracil (TAS-102) plus bevacizumab as a cost effective third line treatment in China but the same was not found in the United States and United Kingdom.
Read More
Defining Value in Oncology Pharmacy: Insights on Care and Costs
October 10th 2024The theme of our inaugural regional Institute for Value-Based Medicine® event in Boston was, “Elevating Value in Cancer Care,” and one of the 4 panel discussions focused on the important contributions of pharmacists and the practice of pharmacy to the oncology space.
Watch
Managing Germline Mutations in Hereditary Breast Cancer Risk
October 7th 2024Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.
Read More
The Price of Progress: Understanding Innovation and Affordability of Prescription Drugs
October 7th 2024Economic incentives and patent protections drive development of innovative medications. Drug prices are determined by consumer demand, not production costs. Therefore, governmental regulation risks future investment in research and development.
Read More
Corporate Accountability and Public Health: Sackler Ruling and Treatment Gaps in the Opioid Crisis
October 2nd 2024The Supreme Court’s decision, paired with the newest data demonstrating the public impact of the opioid crisis, illustrates the legal potential in addressing the crisis and the ongoing public health challenges of treatment access.
Read More
Lower Drug Costs on the Horizon for Medicare Beneficiaries
September 30th 2024Average Medicare drug premiums for older Americans will drop next year for those enrolled in traditional Medicare plans or who have coverage through Medicare Advantage, with opinions divided along party lines on the economic implications.
Read More
At-Home Cholesterol Screening Accessible Through New Program
September 30th 2024The innovative program from the Family Heart Foundation includes being able to order a free test kit for an at-home blood lipid panel and track your results online, as well as the ability to discuss the findings with care navigators and health care providers.
Read More
Role of the Pharmacist in the Care Team to Contain Costs in Oncology
September 28th 2024The pharmacist is a critical member of the care team to help manage patients on treatment and contain costs of cancer care, said Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy, Minnesota Oncology.
Watch
Uplifting Rural Behavioral Health: Leveraging Grants for Lasting Impact
September 27th 2024This interview accompanies the fourth podcast in our National Recovery Month series with Amy Herschell, PhD, associate vice president, Program Implementation and Evaluation, Community Care Behavioral Health Organization, part of the UPMC Insurance Services Division, and Jessica Meyers, MSEd, senior advisor for implementation, UPMC Center for High-Value Health Care.
Watch
State Policy Opportunities to Control Health Care Prices: A CPR Report
September 25th 2024Catalyst for Payment Reform (CPR) explores stakeholder perspectives in Florida, Michigan, and Nevada, revealing both the challenges and opportunities states face in reforming health care pricing structures.
Read More